News › Clinical Practice, Industry News, Patient Care

FDA approves HA filler for midface via cannula injection

November 30, 2018

Galderma Laboratories announced in November 2018 that the FDA approved its hyaluronic acid dermal filler Restylane Lyft for correction of age-related midface deformities and cheek augmentation via a small blunt tip cannula.
One of the biggest debates in aesthetic medicine today is whether dermal fillers are best injected using cannulas or needles, according to Manhattan-based dermatologist Anne Chapas, M.D. Dr. Chapas was an investigator for the Galderma midface cannula study, which led to the FDA’s most recent approval for Restylane Lyft.
Read more at The Aesthetic Channel >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Just Digital Launches Aesthera Marketing, a Dedicated Agency for Med Spas and Aesthetic Practices
    • AI Visibility Report Details How Patients Can Find Your Brand
    • RealSelf Q1 2026 Trend Report Reveals Surge in Regenerative Aesthetics, Skin Rejuvenation
    • Biohacking Beauty: How to Elevate Aesthetic Medicine with Peptides
    • Pacific Reliance Medical M&A Advisors to Broker Sale of 21 Face to Face Medical Spa Locations